Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis

American Journal of Emergency Medicine

Volumn 34, Issue 9, 2016, Pages 1876-1882

  Zhang, Chao ^a   Wang, Huijuan ^a   Yang, Huqin ^a   Tong, Zhaohui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT THROMBOMODULIN; RECOMBINANT PROTEIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

BLEEDING; COCHRANE LIBRARY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; EMBASE; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; HEALTH; HOSPITAL MORTALITY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME FACTOR; TRENDS;

DISSEMINATED INTRAVASCULAR COAGULATION; GLOBAL HEALTH; HOSPITAL MORTALITY; HUMANS; INFECTION; PROPENSITY SCORE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOMODULIN; TIME FACTORS;

EID: 84978977514     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2016.06.001     Document Type: Review

References (34)

1. [1] Ito, T, Maruyama, I, Thrombomodulin: protectorate god of the vasculature in thrombosis and inflammation. J Thromb Haemost 9:Suppl. 1 (2011), 168–173.
2. [2] Toh, CH, Dennis, M, Disseminated intravascular coagulation: old disease, new hope. BMJ 327:7421 (2003), 974–977.
3. [3] Wada, H, Wakita, Y, Nakase, T, Shimura, M, Hiyoyama, K, Nagaya, S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun, Mie DIC Study Group. Thromb Haemost 74:3 (1995), 848–852.
4. [4] Gando, S, Saitoh, D, Ishikura, H, Ueyama, M, Otomo, Y, Oda, S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care, 17(6), 2013, R297.
5. [5] Zarychanski, R, Abou-Setta, AM, Kanji, S, Turgeon, AF, Kumar, A, Houston, DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta analysis. Crit Care Med 43:3 (2015), 511–518.
6. [6] Dellinger, RP, Levy, MM, Carlet, JM, Bion, J, Parker, MM, Jaeschke, R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:1 (2008), 296–327.
7. [7] Di Nisio, M, Baudo, F, Cosmi, B, D'Angelo, A, De Gasperi, A, Malato, A, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 129:5 (2012), e177–e184.
8. [8] Iba, T, Gando, S, Thachil, J, Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 12:7 (2014), 1010–1019.
9. [9] Wada, H, Matsumoto, T, Yamashita, Y, Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care Med, 2(1), 2014, 15.
10. [10] Miyoshi, S, Ito, R, Katayama, H, Dote, K, Aibiki, M, Hamada, H, et al. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther 8 (2014), 1211–1219.
11. [11] Hayakawa, K, Tamura, S, Gima, H, Hayakawa, T, Kurihara, T, Ooura, M, et al. Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm. Rinsho Ketsueki 55:11 (2014), 2300–2305.
12. [12] Murata, A, Okamoto, K, Mayumi, T, Muramatsu, K, Matsuda, S, Recent change in treatment of disseminated intravascular coagulation in Japan:an epidemiological study based on a national administrative database. Clin Appl Thromb Hemost 22:1 (2016), 21–27.
13. [13] Iba, T, Thachil, J, Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis–associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol 103 (2016), 253–261.
14. [14] Yamakawa, K, Aihara, M, Ogura, H, Yuhara, H, Hamasaki, T, Shimazu, T, Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 13:4 (2015), 508–519.
15. [15] Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group, Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 89 (2009), 873–880.
16. [16] Higgins, JPT, Green, S, Cochrane Handbook for Systematic Review of Interventions Version 5.1.0. [updated in March 2011]. The Cochrane collaboration, 2011 [Available from: http://www.cochrane-handbook.org].
17. [17] Vincent, JL, Ramesh, MK, Ernest, D, LaRosa, SP, Pachl, J, Aikawa, N, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART–123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41:9 (2013), 2069–2079.
18. [18] Murata, A, Okamoto, K, Mayumi, T, Muramatsu, K, Matsuda, S, Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation. Int J Clin Pharm 37:1 (2015), 139–147.
19. [19] Hayakawa, M, Yamakawa, K, Saito, S, Uchino, S, Kudo, D, Iizuka, Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation: a multicentre retrospective study. Thromb Haemost 115:6 (2016), 1157–1166.
20. [20] Yamato, M, Minematsu, Y, Fujii, J, Mori, K, Minato, T, Miyagawa, S, et al. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Ther Apher Dial 17:5 (2013), 472–476.
21. [21] Saito, H, Maruyama, I, Shimazaki, S, Yamamoto, Y, Aikawa, N, Ohno, R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:1 (2007), 31–41.
22. [22] Aikawa, N, Shimazaki, S, Yamamoto, Y, Saito, H, Maruyama, I, Ohno, R, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 35 (2011), 349–354.
23. [23] Tagami, T, Matsui, H, Fushimi, K, Yasunaga, H, Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation. Front Med (Lausanne), 2, 2015, 7.
24. [24] Tagami, T, Matsui, H, Horiguchi, H, Fushimi, K, Yasunaga, H, Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 13:1 (2015), 31–40.
25. [25] Takazono, T, Nakamura, S, Imamura, Y, Yoshioka, S, Miyazaki, T, Izumikawa, K, et al. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients. J Infect Chemother 20:8 (2014), 484–488.
26. [26] Ito, T, Kawahara, K, Okamoto, K, Yamada, S, Yasuda, M, Imaizumi, H, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28:10 (2008), 1825–1830.
27. [27] Shi, CS, Shi, GY, Hsiao, SM, Kao, YC, Kuo, KL, Ma, CY, et al. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation. Blood 112:9 (2008), 3661–3670.
28. [28] Van de Wouwer, M, Plaisance, S, De Vriese, A, Waelkens, E, Collen, D, Persson, J, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4:8 (2006), 1813–1824.
29. [29] Yamakawa, K, Ogura, H, Fujimi, S, Morikawa, M, Ogawa, Y, Mohri, T, et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 39:4 (2013), 644–652.
30. [30] Moll, S, Lindley, C, Pescatore, S, Morrison, D, Tsuruta, K, Mohri, M, et al. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2:10 (2004), 1745–1751.
31. [31] Yoshimura, J, Yamakawa, K, Ogura, H, Umemura, Y, Takahashi, H, Morikawa, M, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care, 19, 2015, 78.
32. [32] Kato, T, Sakai, T, Kato, M, Hagihara, M, Hasegawa, T, Matsuura, K, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J, 11(1), 2013, 3.
33. [33] Ogawa, Y, Yamakawa, K, Ogura, H, Kiguchi, T, Mohri, T, Nakamori, Y, et al. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 72:5 (2012), 1150–1157.
34. [34] Hashimoto, D, Chikamoto, A, Miyanari, N, Ohara, C, Kuramoto, M, Horino, K, et al. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation. J Surg Res 197:2 (2015), 405–411.